Recently, Tianjin Pharmaceutical Group's subsidiary, Tianjin Pharmaceutical Peace, obtained a registration certificate from the Ministry of Health of the Dominican Republic for its product, methylprednisolone sodium succinate for injection (specifications: 125mg and 500mg), marking that it can produce and sell the drug in the Dominican Republic market.

It is understood that methylprednisolone sodium succinate for injection is a glucocorticoid drug, mainly used for anti-inflammatory treatment, immunosuppressive therapy, treatment of hematological diseases and tumors, and treatment of shock. In 2023, Tianjin Pharmaceutical Peace submitted a registration application to the Ministry of Health of the Dominican Republic, and in April 2025, it received notification from the Ministry of Health that it had obtained the registration certificate.

The registration certificate obtained for this drug will have a positive impact on Tianjin Pharmaceutical's expansion into the Dominican Republic's pharmaceutical market and on improving the company's performance.

Manuscript: Board Office of Tianjin Pharmaceutical Group